Two New Therapies Show Promise for Cancer Patients

---

Omschrijving
Clinical trial data and cutting-edge testing give key insights in the fight against basal cell carcinoma and pancreatic cancer. San Diego and Phoenix—April 15, 2008—Clinical researchers at Scottsdale Healthcare and TGen today announced the results of two clinical trials that show promise for patients battling cancer. The Phase I clinical trial findings, presented at the this weeks Annual Meeting of the American Association for Cancer Research by Daniel Von Hoff, MD, FACG, focused on basal cell carcinoma (BCC) and pancreatic cancer. The Arizona trials were conducted at TGen's Clinical Research Service (TCRS) at Scottsdale Healthcare, a strategic alliance between TGen and Scottsdale Healthcare’s Clinical Research Institute. Basal Cell Carcinoma In the first trial, a novel molecule, GDC-0449, shrinks tumors in basal cell carcinoma (BCC) while having limited side effects, including a loss of sense of taste, and a small amount of hair loss and weight loss, suggesting a viable new treatment option. GDC-0449 works by blocking a pathway — a series of chemical reactions within a cell— known as Hedgehog, containing two genes (PTCH and SMO) that lead to a known tumor-promoting gene called GLI1. Alterations in any of these genes have been shown to lead to basal cell carcinoma and other diseases. GDC-0449 is a chemical synthetic designed to replicate the properties of cyclopamine, a chemical found in nature.

 

[ Ga naar het volledige artikel toe ]

Categorie: alvleesklierkanker

[Reinig uw lichaam met de Chlorella alg - 100% plantaardig ]

Het hoofdmenu
Nieuws
Supervoeding
Zoek op onderwerp